Sophia Genetics

Last updated

Sophia Genetics SA
Company type Public
Nasdaq:  SOPH
Industry Software
Cloud computing
Founded2011;13 years ago (2011)
Founders
  • Dr. Jurgi Camblong
  • Prof. Lars Steinmetz
  • Dr. Pierre Hutter
Headquarters
Lausanne, Switzerland
Boston, United States
Key people
  • Dr. Jurgi Camblong (CEO)
  • Ross Muken (CFO)
  • Philippe Menu (CMO) [1]
ServicesSophia DDM Platform
Number of employees
500+
Website sophiagenetics.com

Sophia Genetics SA is a data-driven medicine software company with headquarters in Lausanne, Switzerland and Boston, Massachusetts. [2] [3] [4] [5] It provides genomic and radiomic analysis for hospitals, laboratories, and biopharma institutions. [6] [7] The company was ranked among the 50 smartest companies by the MIT Technology Review in 2017. [8] The company went public on the Nasdaq in 2021, floating at $1.1B. [9]

Contents

History

Sophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz in 2011 as a start-up at École Polytechnique Fédérale de Lausanne (EPFL). It began as a research tool for hospitals and federally regulated health care labs, and then expanded to biopharma institutions. [10]

In 2014, the company introduced an analytical software platform, the Sophia DDM Platform (Data-Driven Medicine), [11] [12] which helps to interpret circulating tumor DNA and circulating tumour cells in blood, urine, cerebral spinal fluid and other liquid samples. [13] The Sophia DDM Platform is a cloud-based, Software-as-a-Service that uses machine learning and AI algorithms to provide genomic insights to doctors and researchers from complex multimodal datasets. [14] [15] Insights are shared across the platform with all participating institutions. [14] This means that as the user-base scales, the AI becomes smarter and more accurate as it’s fed more data. [13] The platform is used for oncology, hereditary cancers, metabolic disorders, pediatrics, cardiology, and for rare disease research. [13]

The company initially designed the platform to help hospitals with processing and storing large genomic data-sets, but research showed that the more pressing problem was data accuracy. [13] That then became the platform's primary focus. The startup worked with hospitals to benchmark DNA samples analyzed via their sequencing systems, and then trained algorithms of their own to perform the diagnosing process automatically and recognize relevant patterns in the genome data. [13] The algorithms were built bottom-up from raw FASTQ data. [13]

To use the platform, DNA is extracted from a patient sample, enriched, and sequenced by an NGS machine. [13] Once this data has been digitized, it is loaded into the platform. The SOPHiA DDM Platform's AI algorithms then pull out unique genetic variants and pre-classifies data according to pathogenic predictions. [13] Doctors and researchers can then review the detected variants and take action – the SOPHiA DDM Platform in turn learns from those actions [13]

In 2017, Sophia Genetics was ranked as one of the 50 smartest companies in the world by the MIT Tech Review. [8]

In 2018, the company set up its first research and development center in France and made acquisition of a France-based molecular biology and genetic analytics software development company, Interactive Biosoftware. [16] [17] That same year, Sophia Genetics opened its U.S. headquarters in Boston, Massachusetts. [18] At the time, the company was supporting more than 100 university hospitals in the U.S. [18] It also received the Salus Partner Excellence in HealthTech Award in 2018. [19]

In 2020, the company appointed Troy Cox, former board of directors member, as its new chairman, [20] [21] and Lara Hashimoto as chief business officer. [22] In August, the company released a data analysis solution that was focused on predicting the disease evolution of the SARS-CoV-2 virus. [23] The platform’s AI system was designed to conduct a full-genome analysis of the virus. It then combines that data with patient genetic information, and clinical data such as the results of lung and CT scans to discover abnormalities predictive of disease evolution. [23] Sophia Genetics also received the Best Overall Genomics Company in the 2020 MedTech Breakthrough Awards. [24]

In 2021, the company was named a Microsoft Partner of the Year finalist [25] and went public, now listed on the Nasdaq. At the time, its platform was in use at more than 750 hospitals, laboratories, and biopharma institutions around the world and had analyzed over 770,000 genomic profiles worldwide. [14] [15]

In 2022, Sophia Genetics was named one of the 100 Best Places to Work in Boston by Built in Boston. [26]

Also in 2022, the firm began development of a new method for detecting extrachromosomal DNA through collaboration with startup firm Boundless Bio. [1]

Funding

The company has been through multiple rounds of funding.

In September 2013, as part of a Series A round of funding, Sophia Genetics received $3 million for its medical software platform. [13]

A Series B round of funding in 2014 raised $13.75 million from Swisscom and Endeavour Vision. [27]

In a December 2015 Series C round of funding, Sophia Genetics raised $15 million from Omega Pharma founder and healthcare scion Marc Coucke. [28]

In September 2017, as part of a Series D round of funding, the company received $30 million from UK-based VC firm Balderton Capital to its investor list. [13]

The company raised $77 million in January 2019 as part of a Series E round of funding. The round was led by Generation Investment Management. [3] [29] [30]

In October 2020, as part of a Series F round of funding, The company raised $110 million. The round was led by aMoon a health-tech and life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group. [31]

In 2021, Sophia Genetics went public, trading under the symbol SOPH on the Nasdaq. [32] [33] The company raised $234 million in its IPO and was backed by J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse. [33]

Partnership

In 2016, Sophia Genetics entered into a comarketing agreement with Illumina allowing the two companies to promote adoption of next- generation DNA sequencing. [34]

In 2019, Sophia Genetics formed partnerships with Integrated DNA Technologies and Paragon Genomics, next-generation sequencing (NGS) assay development company, to provide COVID-19 test kits [35] [36]

In 2021, the company partnered with MGI, a subsidiary of BGI Group, to enable their users to access the SOPHiA DDM Platform for data analysis and interpretation. [37] In March 2021, Sophia Genetics announced a long-term collaboration agreement with Hitachi. [38] In July of that year, Sophia Genetics joined with GE Healthcare to match cancer patients to the best possible treatment plans based on their specific genomic signature, cancer type, and overall health history. [39] The partnership combines technologies from Sophia DDM Platform and GE’s medical imaging and monitoring tools, as well as the Edison data aggregation platform. [40] The companies will also research additional opportunities for collaboration in the fields of digital oncology and radiogenomic analysis . [15]

In 2022, the firm committed to a collaboration with Memorial Sloan Kettering Cancer Center to advance predictive tumor analysis and, more broadly, clinical decision support. [1] This benefits the firm in part by providing access to MSK-IMPACT, the Center's proprietary tumor sequencing database. [1]

Related Research Articles

<span class="mw-page-title-main">BGI Group</span> Chinese genome sequencing company

BGI Group, formerly Beijing Genomics Institute, is a Chinese genomics company with headquarters in Yantian, Shenzhen. The company was originally formed in 1999 as a genetics research center to participate in the Human Genome Project. It also sequences the genomes of other animals, plants and microorganisms.

deCODE genetics is a biopharmaceutical company based in Reykjavík, Iceland. The company was founded in 1996 by Kári Stefánsson with the aim of using population genetics studies to identify variations in the human genome associated with common diseases, and to apply these discoveries "to develop novel methods to identify, treat and prevent diseases."

<span class="mw-page-title-main">Personalized medicine</span> Medical model that tailors medical practices to the individual patient

Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept, though some authors and organizations differentiate between these expressions based on particular nuances. P4 is short for "predictive, preventive, personalized and participatory".

<span class="mw-page-title-main">George Church (geneticist)</span> American geneticist

George McDonald Church is an American geneticist, molecular engineer, chemist, serial entrepreneur, and pioneer in personal genomics and synthetic biology. He is the Robert Winthrop Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard University and Massachusetts Institute of Technology, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard University.

Personal genomics or consumer genetics is the branch of genomics concerned with the sequencing, analysis and interpretation of the genome of an individual. The genotyping stage employs different techniques, including single-nucleotide polymorphism (SNP) analysis chips, or partial or full genome sequencing. Once the genotypes are known, the individual's variations can be compared with the published literature to determine likelihood of trait expression, ancestry inference and disease risk.

DNAnexus is an American company that provides a cloud-based data analysis and management platform for DNA sequence data. It is based in Mountain View, California, and was founded in 2009 by Stanford University professors Serafim Batzoglou and Arend Sidow and Stanford computer scientist Andreas Sundquist.

Tute Genomics is a genomics startup that provides a cloud-based web application for rapid and accurate annotation of human genomic data. Built on the expertise of ANNOVAR, Tute assists researchers in identifying disease genes and biomarkers, and assists clinicians/labs in performing genetic diagnosis. Based in Provo, Utah, Tute was co-founded by Dr. Kai Wang, an Assistant Professor at the University of Southern California (USC); and Dr. Reid J. Robison, a board-certified psychiatrist with fellowship training in both neurodevelopmental genetics and bioinformatics.

The 100,000 Genomes Project is a now-completed UK Government project managed by Genomics England that is sequencing whole genomes from National Health Service patients. The project is focusing on rare diseases, some common types of cancer, and infectious diseases. Participants give consent for their genome data to be linked to information about their medical condition and health records. The medical and genomic data is shared with researchers to improve knowledge of the causes, treatment, and care of diseases. The project has received over £300 million from public and private investment.

Foundation Medicine, Inc. is an American company based in Cambridge, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.

<span class="mw-page-title-main">OS Fund</span> American venture-capital fund

OS Fund is an American venture capital fund that invests in early-stage science and technology companies.

Human Longevity, Inc. is a San Diego-based venture launched by Craig Venter and Peter Diamandis in 2013. Its goal is to build the world's most comprehensive database on human genotypes and phenotypes, and then subject it to machine learning so that it can help develop new ways to fight diseases associated with aging. The company received US$80 million in investments in its Series A offering in summer 2014 and announced a further $220 million Series B investment offering in April 2016. It has made deals with drug companies Celgene and AstraZeneca to collaborate in its research.

Foresite Capital (Foresite) is an American, multi-stage healthcare and life sciences investment firm headquartered in Los Angeles, and with offices in the The San Francisco Bay Area and New York City. As of June 2024, the company had raised six primary funds: Foresite Capital Fund I, II, III, IV, V and VI.

<span class="mw-page-title-main">Insilico Medicine</span> Biotechnology company

Insilico Medicine is a biotechnology company based in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.

<span class="mw-page-title-main">Intellia Therapeutics</span> American biotechnology company

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

<span class="mw-page-title-main">Helmy Eltoukhy</span> American scientist and entrepreneur

Helmy Eltoukhy is an American scientist and a businessperson who co-founded startups Avantome and Guardant Health. He is best known for his contributions to genomics, semiconductor DNA sequencing, and personalized medicine. His startups were acquired by Illumina in 2008. Avantome was founded to develop and commercialize semiconductor-based DNA sequencing, during the race for the $1,000 genome. Guardant Health was founded to pioneer non-invasive liquid biopsy approaches for cancer diagnosis, monitoring, personalized medicine treatment, and research.

Colossal Biosciences Inc. is an American biotechnology and genetic engineering company working to de-extinct the woolly mammoth, the Tasmanian tiger, and the dodo. In 2023, it stated that it wants to have woolly mammoth hybrid calves by 2028, and wants to reintroduce them to the Arctic tundra habitat. Likewise, it launched the Tasmanian Thylacine Advisory Committee, a thylacine research project to release Tasmanian tiger joeys back to their original Tasmanian and broader Australian habitat after a period of observation in captivity.

Personalized genomics is the human genetics-derived study of analyzing and interpreting individualized genetic information by genome sequencing to identify genetic variations compared to the library of known sequences. International genetics communities have spared no effort from the past and have gradually cooperated to prosecute research projects to determine DNA sequences of the human genome using DNA sequencing techniques. The methods that are the most commonly used are whole exome sequencing and whole genome sequencing. Both approaches are used to identify genetic variations. Genome sequencing became more cost-effective over time, and made it applicable in the medical field, allowing scientists to understand which genes are attributed to specific diseases.

<span class="mw-page-title-main">MGI (company)</span> Chinese biotechnology company

MGI or MGI Tech is a Chinese biotechnology company, which provides a line of products and technologies that serves the genetic sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in Shenzhen, China.

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

Abasi Ene-Obong, is a Nigerian biomedical scientist and entrepreneur. Abasi holds a master's degree in human molecular genetics from Imperial College London and a PhD in Cancer Biology from Barts and The London School of Medicine and Dentistry in England. Since September 2023, he is the founder and CEO of Syndicate Bio, a health technology company driving genomics and precision medicine initiatives in global healthcare. Prior to this, since 2019, Abasi served as the co-founder and CEO at 54Gene Inc, a defunct Nigerian health and biotech firm specialized in African genomics which he grew to a valuation of nearly $200m before stepping down in October 2022.

References

  1. 1 2 3 4 "Sophia Genetics Partners With MSK on Clinical Decision Support, Boundless Bio on ecDNA Detection" . GenomeWeb . 21 September 2022. Retrieved 21 September 2022.
  2. ↑ "Sophia Genetics - So Far, So Good..." Nasdaq.
  3. 1 2 Lomas, Natasha (4 January 2019). "Sophia Genetics bags $77M Series E, with 850+ hospitals signed up to its 'data-driven medicine'". TechCrunch .
  4. ↑ Murgia, Madhumita (29 November 2015). "Data-driven medicine: Sophia Genetics becomes largest clinical genomics network". The Daily Telegraph . Retrieved 8 July 2019.
  5. ↑ Magistretti, Bérénice (2 January 2017). "Swiss data analytics company Sophia Genetics could be Switzerland's next unicorn". TechCrunch .
  6. ↑ Neil, Joshua (16 April 2019). "An Interview with Sophia Genetics: STS and the CE-IVD Designation". Front Line Genomics. Archived from the original on 24 September 2019.
  7. ↑ Gaskell, Adi; Wall, Matthew (27 April 2018). "How knowing your genetic code could lengthen your life". BBC News . Retrieved 8 July 2019.
  8. 1 2 "50 Smartest Companies". MIT Technology Review . 2017. Retrieved 8 July 2019.
  9. ↑ Kilgore, Tomi (23 July 2021). "Sophia Genetics set to go public at a $1.1 billion valuation". MarketWatch . Retrieved 19 August 2021.
  10. ↑ "Genomics testing firm to triple Boston headcount after $110M round". www.bizjournals.com. Retrieved 7 April 2022.
  11. ↑ "Sophia genetics". techtour.com. Retrieved 6 May 2022.
  12. ↑ Park, Andrea (1 October 2021). "Sophia Genetics teams up with OncoDNA to automate tumor profiling". Fierce Biotech. Retrieved 25 February 2022.
  13. 1 2 3 4 5 6 7 8 9 10 11 Lomas, Natasha (13 September 2017). "Balderton joins $30M Series D for big data biotech platform play, Sophia Genetics". TechCrunch .
  14. 1 2 3 "GE Healthcare and Sophia partner to develop AI-driven cancer solutions". Medical Device Network. 7 July 2021. Retrieved 3 March 2022.
  15. 1 2 3 "GE Healthcare announces three collaborations to advance cancer care". Med-Tech Innovation. 9 December 2021. Retrieved 3 March 2022.
  16. ↑ Lerivrain, Hélène (25 April 2018). "La biotech suisse Sophia Genetics continue d'investir et s'installe au Pays basque". La Tribune (in French).
  17. ↑ Chavanne, Yannick (18 June 2018). "Sophia Genetics rachète un spécialiste mondial de l'exploration de variations génomiques". ICT Journal (in French).
  18. 1 2 "Swiss company sets up US headquarters in Boston". BostonGlobe.com. 24 September 2018. Retrieved 17 March 2022.
  19. ↑ "RefleXion and Sofinnova Partners recognized with Salus Excellence Award". Imaging Technology News. 25 September 2020. Retrieved 12 May 2022.
  20. ↑ Hale, Conor (21 February 2020). "Sophia Genetics taps ex-Foundation Medicine CEO as chairman". FierceBiotech.
  21. ↑ "Sophia Genetics changera de président début mars". AGEFI (in French). 20 February 2020.
  22. ↑ Credi, Mer (8 April 2020). "Sophia Genetics élargit son équipe de direction". AGEFI (in French).
  23. 1 2 Taylor, Phil (10 August 2020). "Sophia Genetics launches AI tool to find COVID-19 'unknowns' -". pharmaphorum.com. Retrieved 24 March 2022.
  24. ↑ "2020 Winners". MedTech Breakthrough. Retrieved 12 May 2022.
  25. ↑ Bekker, Scott. "Social Impact a Focus of the 2021 Microsoft Partner of the Year Awards -". Redmond Channel Partner. Retrieved 21 April 2022.
  26. ↑ "100 Best Places To Work In Boston 2022 | Built In Boston". www.builtinboston.com. Retrieved 5 May 2022.
  27. ↑ "Sophia Genetics Raises $13.8M in Private Financing Round". GenomeWeb . 8 July 2014.
  28. ↑ "Europe's leading entrepreneurs leads Series C Round in Sophia Genetics". Venture Lab. 16 December 2015.
  29. ↑ Wise, James (4 January 2019). "Sophia Genetics announces new $77M funding round". Medium .
  30. ↑ O'Brien, Chris (4 January 2019). "Swiss startup Sophia Genetics raises $77 million to expand its AI diagnostic platform in the U.S." VentureBeat .
  31. ↑ "Sophia Genetics raises $110M to fuel global data platform expansion".
  32. ↑ "Sophia Genetics Raises $234M in IPO, Eyes Additional Partnerships". GenomeWeb.
  33. 1 2 "Sophia Genetics goes public in $234M IPO, two other biotechs delay". Boston Business Journal.
  34. ↑ "Illumina, Sophia Genetics to Comarket NGS Solutions for Clinical Dx". GenomeWeb .
  35. ↑ "IDT, Sophia Genetics Broaden Partnership to Clinical-Grade Technologies". Clinical OMICs - Molecular Diagnostics in Precision Medicine. 17 January 2020.
  36. ↑ "Sophia Genetics, Paragon Genomics Team on SARS-CoV-2 Testing". Clinical OMICs - Molecular Diagnostics in Precision Medicine. 26 March 2020.
  37. ↑ "Sophia Genetics to Provide Access to Genomic Analysis Platform to MGI Customers". GenomeWeb .
  38. ↑ "Hitachi enters collaboration for data driven precision medicine". www.biospectrumasia.com. Retrieved 28 April 2022.
  39. ↑ Park, Andrea (7 July 2021). "GE Healthcare, Sophia Genetics tag-team cancer care with patient-treatment matching tools". Fierce Biotech. Retrieved 14 April 2022.
  40. ↑ "GE Healthcare and Sophia partner to develop AI-driven cancer solutions". Medical Device Network. 7 July 2021. Retrieved 14 April 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.